Cagri (10mg)

$60.00

Cagrilintide is currently being investigated in preclinical and translational studies for:

Obesity & Weight Loss Models: Evaluating reductions in food intake and body weight.

Type 2 Diabetes Research: Studying synergistic effects on glucose and appetite regulation.

Cardiometabolic Health: Exploring roles in cholesterol, triglyceride, and lipid metabolism.

Combination Therapies: Researching dual administration with GLP-1 analogs for enhanced outcomes.

Neuroendocrine Studies: Understanding amylin’s role in central appetite regulation pathways.

Out of stock

Cagrilintide (Cagri)

Molecular Formula: C190H291N51O57
Molecular Weight: ~4020 g/mol
Structure: Long-acting amylin analog
Form: Lyophilized peptide, ≥98% purity
Synonyms: AMG-986, Long-acting amylin receptor agonist

 

Overview

Cagrilintide (often referred to as Cagri) is a synthetic, long-acting amylin analog designed to target amylin and calcitonin receptors involved in appetite and weight regulation. Amylin is a naturally occurring peptide hormone co-secreted with insulin that plays a critical role in satiety signaling, gastric emptying, and glucose control.

Due to its enhanced stability and half-life, Cagrilintide has become an important subject in obesity and metabolic research, especially when studied in combination with GLP-1 receptor agonists such as Semaglutide.

 

Mechanism of Action

In preclinical research, Cagrilintide demonstrates its effects through:

Amylin Receptor Agonism: Activates amylin and calcitonin receptors to regulate appetite and satiety.

Gastric Emptying Delay: Slows gastric emptying, reducing post-meal glucose spikes.

Central Nervous System Modulation: Influences hypothalamic pathways to reduce food intake.

Synergistic Metabolic Effects: Shows enhanced weight-regulating potential when paired with incretin mimetics (e.g., Semaglutide, Tirzepatide).

Extended Half-Life: Structural modifications improve stability, supporting once-weekly dosing in experimental settings.

 

Research Areas

Cagrilintide is currently being investigated in preclinical and translational studies for:

Obesity & Weight Loss Models: Evaluating reductions in food intake and body weight.

Type 2 Diabetes Research: Studying synergistic effects on glucose and appetite regulation.

Cardiometabolic Health: Exploring roles in cholesterol, triglyceride, and lipid metabolism.

Combination Therapies: Researching dual administration with GLP-1 analogs for enhanced outcomes.

Neuroendocrine Studies: Understanding amylin’s role in central appetite regulation pathways.

 

Handling & Storage

Storage (lyophilized): –20°C, protected from light and moisture.

Reconstitution: Reconstitute with sterile water or suitable buffer.

Stability: Store reconstituted peptide at 2–8°C and avoid repeated freeze–thaw cycles.

 

Disclaimer

Cagrilintide is intended exclusively for laboratory and preclinical research purposes.
It is not approved for human or veterinary use and must not be used in diagnostic, therapeutic, or self-administration contexts. All research use should remain within controlled laboratory environments.

Shopping Cart
Scroll to Top

You need to be 21 above to access this store

Entering this website means you’re agreeing to our Terms and services

DISCLAIMER: Products supplied by Independent Peptides are intended exclusively for laboratory research use. They are not approved for human or animal consumption and must not be used for any medical, diagnostic, or therapeutic purposes.